Reig Jofre Secures €13M Grant to Accelerate Pharma Innovation and Expansion

We are thrilled to announce that Reig Jofre has successfully raised €13,000,000 in fresh funding, marking a significant milestone in our company’s journey of growth and innovation. Since December 2014, following the merger between Laboratorio Reig Jofre SA and Natraceutical SA, we have proudly established ourselves as the fifth Spanish pharma company listed on the stock exchange (ticker: RJF). This considerable infusion of capital will fuel our strategic plans to further expand our research, development, manufacturing, and marketing efforts across our diverse portfolio of medicines and food supplements—as well as our specialized third-party manufacturing services. With a robust commitment to deepening our focus on innovative research and development, this funding will primarily be channeled towards advancing our work on generating new indications and/or dosage forms of established active principles. Our investment will also support the scaling up of our production capabilities in key areas such as beta lactam and lyophilized injectable antibiotics, topical dermatological products, OTCs, and nutritional supplements. Moreover, the capital will empower us to accelerate the development of innovative molecules in valuable partnerships with start-ups and esteemed research centers, ensuring that we remain at the forefront of cutting-edge pharmaceutical solutions. As we leverage this new financial strength, our goal remains steadfast—to continue improving healthcare outcomes through rigorous science, sustainable innovation, and strategic collaboration. For further information about our initiatives and vision, we invite you to visit our website and join us as we embark on this exciting new chapter in redefining the future of pharma.